The first product of Immungenetics AG will be a test array enabling the examination of different genetic markers of patients who have already been diagnosed with Multiple Sclerosis (or another immune mediated disease).
These markers have been generated by statistically evaluating large human cohorts including the detailed medical record and the respective genetic disposition of the patient.
The advantage of this marker analysis is that due to the individual information on the genome of the patient early predictions on the course of the disease, tolerance and effectiveness of certain medication and therapies can be made.
Thus, the attending doctor is able to adapt a therapy directly to the respective patient. By means of this test array it will hence be possible to improve therapies, increase the quality of life for patients and also save costs for ineffective treatments.